Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anne-Gaëlle Dosne"'
Autor:
Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Ruben Faelens, Quentin Leirens, Italo Poggesi, Juan Jose Perez Ruixo
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 5, Pp 569-580 (2022)
Abstract A population pharmacokinetic (PK)–pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK‐PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate c
Externí odkaz:
https://doaj.org/article/d207019ca52a4083a1ee53c5220eb93b
Autor:
Louis, Sandra, Huybrecht, T'jollyn, Nele, Goeyvaerts, An, Vermeulen, Anne-Gaëlle, Dosne, Juan-Jose, Perez-Ruixo
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 383:70-79
JNJ-73763989 is an N-acetylgalactosamine conjugated short interfering RNA combination product consisting of two triggers in clinical development for chronic hepatitis B virus (HBV) infection treatment that induces a selective degradation of all HBV m
Autor:
Juan-José Pérez-Ruixo, Yaowei Zhu, Martine Neyens, Marie-Helene Jouvin, Sindhu Ramchandren, Yan Xu, Jocelyn Leu, Anne-Gaëlle Dosne, Yuan Xiong, Belén Valenzuela, Leona Ling, Partha Nandy, Hong Sun
Publikováno v:
Sunday, April 23.
Autor:
Anne-Gaëlle Dosne, Elodie Valade, Nele Goeyvaerts, Peter De Porre, Anjali Avadhani, Anne O’Hagan, Lilian Y. Li, Daniele Ouellet, Juan Jose Perez Ruixo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:151-164
Background Exposure–response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced or metastati
Autor:
Italo Poggesi, Anjali Narayan Avadhani, Peter De Porre, Ruben Faelens, Lilian Y. Li, Daniele Ouellet, Quentin Leirens, Anne OHagan, Juan Jose Perez Ruixo, Elodie Valade, Anne-Gaëlle Dosne, Kim Stuyckens
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:569-580
A population pharmacokinetic (PK)-pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK-PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate concentrations
Autor:
Jorge Vialard, Timothy Perera, Tinne Verhulst, Elena Maria Tosca, Paolo Magni, Nadia Terranova, Peter King, Anne-Gaëlle Dosne, Kim Stuyckens, Juan Jose Perez-Ruixo, Italo Poggesi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 89:117-128
Erdafitinib (JNJ-42756493, BALVERSA) is a tyrosine kinase inhibitor indicated for the treatment of advanced urothelial carcinoma. In this work, a translational model-based approach to inform the choice of the doses in phase 1 trials is illustrated. A
Autor:
Juan Jose Perez-Ruixo, Elodie Valade, Anne-Gaëlle Dosne, Kim Stuyckens, Daniele Ouellet, Lilian Y. Li
Publikováno v:
The Journal of Clinical Pharmacology. 60:515-527
A population pharmacokinetic (PK) model was developed using data pooled from 6 clinical studies (3 in healthy volunteers and 3 in cancer patients) to characterize total and free plasma concentrations of erdafitinib following single- and multiple-dose
Autor:
Juan Jose Perez-Ruixo, Paolo Magni, Roberta Bartolucci, Dénes Csonka, Anne-Gaëlle Dosne, Italo Poggesi
Publikováno v:
Clinical pharmacokinetics. 60(12)
Macitentan and its active metabolite, aprocitentan, are non-peptide, potent, dual endothelin receptor antagonists. Macitentan is approved for the treatment of pulmonary arterial hypertension in adults, at a dose of 10 mg/day. The objective of this st
Publikováno v:
Statistics in Medicine. 36:3844-3857
Assessing the QT prolongation potential of a drug is typically done based on pivotal safety studies called thorough QT studies. Model-based estimation of the drug-induced QT prolongation at the estimated mean maximum drug concentration could increase
Publikováno v:
Cpt Pharmacometrics and Systems Pharmacology, 5, 12, pp. 682-691
CPT: Pharmacometrics & Systems Pharmacology
Cpt Pharmacometrics and Systems Pharmacology, 5, 682-691
CPT: Pharmacometrics & Systems Pharmacology
Cpt Pharmacometrics and Systems Pharmacology, 5, 682-691
Albumin concentration and body weight are altered in patients with multidrug-resistant tuberculosis (MDR-TB) and change during the long treatment period, potentially affecting drug disposition. We here describe the pharmacokinetics (PKs) of the novel